Rare disease

Paroxysmal Nocturnal Haemoglobinuria

Clinical trials recruiting in Australia for Paroxysmal Nocturnal Haemoglobinuria, a rare disease, as the public registries list them.

Also called: Marchiafava-Micheli disease; PNH; Paroxysmal nocturnal hemoglobinuria; Marchiafava-Micheli syndrome

Sources: ClinicalTrials.gov, MedlinePlus, Orphanet Checked: 11 October 2026 Not medical advice

At a glance

2 trials recruiting in Australia

42 trials recruiting overseas

1-9 / 100 000 (Point prevalence, United Kingdom, Validated) prevalence

All ages age of onset

11 October 2026 date last checked

Trials in Australia

This Australian count is likely to be on the low side. It counts the trials this site files under this condition; the registry’s own search is broader and also returns closely related conditions, some of which have their own page here. If you are searching widely, check the registry as well — every trial below links to its own record.

  • Recruiting Phase 2

    Phase 2 study for people with Paroxysmal Nocturnal Haemoglobinuria

    Where
    • Nucleus Network Brisbane, Brisbane (QLD) — Completed
    • Peter MacCallum Cancer Centre, Melbourne (VIC) — Completed
    • Royal Melbourne Hospital, Parkville (VIC) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Accepted.
    Sponsor ADARx Pharmaceuticals, Inc.
    Timeline
    Started 7 August 2023 Today 16 October 2026 Estimated completion 31 March 2028

    NCT05876312 · Checked 11 October 2026

  • Recruiting Not a phased study

    Study for people with Paroxysmal Nocturnal Haemoglobinuria

    Where

    No Australian site on this record is listed as recruiting right now, even though the trial itself is open. Check with the site or the official record before travelling.

    • Research Site, Melbourne (VIC) — Not yet recruiting
    Who can join Age child, adult, older adult. Sex Female participants only. Healthy volunteers Not accepted.
    Sponsor Alexion Pharmaceuticals, Inc.
    Timeline
    Started 16 December 2024 Today 16 October 2026 Estimated completion 11 July 2034

    NCT06312644 · Checked 11 October 2026

Trials overseas

42 trials for this disease are open to new participants outside Australia, as ClinicalTrials.gov listed them on 11 October 2026. Voxsanity does not publish a page for any of them; the searches below reach them at the registry.

These overseas counts are likely too high. They come from the registry’s own search, which expands a condition name to related conditions, so some of the trials counted are for a different disease in the same family.

Trials not shown here

Some Australian trials are registered only on the Australian New Zealand Clinical Trials Registry and are not shown here. Search them at Australian Clinical Trials.

Key facts

Inheritance Not applicable
Genes PIGA
Prevalence 1-9 / 100 000 (Point prevalence, United Kingdom, Validated)
Age of onset All ages

Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com).

About Paroxysmal Nocturnal Haemoglobinuria

The text below is reproduced exactly as its source published it. It has not been edited, shortened or rewritten.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired (not inherited) disorder that leads to the premature death and impaired production of blood cells. The disorder affects red blood cells (erythrocytes), which carry oxygen; white blood cells (leukocytes), which protect the body from infections; and platelets (thrombocytes), which are involved in blood clotting. PNH can occur at any age, although it is most often diagnosed in young adulthood. People with PNH have sudden, recurring episodes of symptoms (paroxysmal symptoms), which may be triggered by stresses on the body, such as infections or physical exertion. During these episodes, red blood cells are broken down earlier than they should be (hemolysis). Affected individuals may pass dark-colored urine because of the presence of hemoglobin, the oxygen-carrying protein in blood. The abnormal presence of hemoglobin in the urine is called hemoglobinuria. In many, but not all cases, hemoglobinuria is most noticeable early in the morning, upon passing urine that has accumulated in the bladder during the night (nocturnal). The premature breakdown of red blood cells results in a shortage of these cells in the blood (hemolytic anemia), which can cause signs and symptoms such as fatigue, weakness, abnormally pale skin (pallor), shortness of breath, and an increased heart rate (tachycardia). People with PNH may also be prone to infections because of a shortage of white blood cells (leukopenia). Abnormal platelets associated with PNH can cause problems in the blood clotting process. As a result, people with this disorder may experience abnormal blood clotting (thrombosis), especially in large abdominal veins; or, less often, episodes of severe bleeding (hemorrhage). Individuals with PNH are at increased risk of developing cancer in blood-forming cells (leukemia). In some cases, people who have or have been treated for another blood disease called aplastic anemia may develop PNH. In a small number of affected individuals, the signs and symptoms of PNH disappear on their own. A very rare form of PNH involves abnormal inflammation in addition to the typical features described above. Inflammation is a normal immune system response to injury and foreign invaders (such as bacteria). In people with this rare form of PNH, the immune response is turned on (activated) abnormally and can cause recurrent aseptic meningitis (which is inflammation of the membranes surrounding the brain and spinal cord that is not related to infection); a red, itchy rash (known as hives or urticaria); joint pain (arthralgia); or inflammatory bowel disease. The inflammatory disorders usually begin earlier than the blood cell problems.

US source; availability in Australia may differ.

Source: MedlinePlus Genetics (medlineplus.gov), public domain (U.S. National Library of Medicine). Read the full source.

Sources and dates

  • ClinicalTrials.gov – trial records, statuses and site lists
  • MedlinePlus – the About text above, reproduced exactly
  • Orphanet / Orphadata – prevalence, age of onset, inheritance, genes and alternative names, used under CC BY 4.0
  • ClinicalTrials.gov processing date: 16 June 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Orphanet citation

Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com). Accessed 20 September 2026.

ORPHA:447

Tell us which conditions matter to you

We use requests to help decide what to add next. Telling us about a condition is not a promise that we will add it, and we cannot say when any condition might appear.